| value |
{"aggregator_url":"https://www.nasdaq. {"aggregator_url":"https://www.nasdaq.com/articles/tempus-ai-expands-collaboration-gilead-sciences-maximize-insights-oncology-pipeline","as_of":"2026-04-09T13:37:34.641242+00:00","canonical_url":"https://www.rttnews.com/3637925/tempus-ai-expands-collaboration-with-gilead-sciences-to-maximize-insights-in-oncology-pipeline.aspx","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/tempus-ai-expands-collaboration-gilead-sciences-maximize-insights-oncology-pipeline","article_chars":2237,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_2ce841ec125faba7","canonical_host":"rttnews.com","canonical_is_aggregator":false,"canonical_url":"https://www.rttnews.com/3637925/tempus-ai-expands-collaboration-with-gilead-sciences-to-maximize-insights-in-oncology-pipeline.aspx","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-10T00:34:16.876861+00:00","extraction_method":"heuristic","fetched_description":"(RTTNews) - Healthcare technology company Tempus AI, Inc. (TEM) Thursday announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (GILD) to build and advance its oncology pipeline.","fetched_title":"Tempus AI Expands Collaboration With Gilead Sciences To Maximize Insights In Oncology Pipeline | Nasdaq","final_url":"https://www.nasdaq.com/articles/tempus-ai-expands-collaboration-gilead-sciences-maximize-insights-oncology-pipeline","html_truncated":false,"paywall_likely":false,"publisher_domain":"rttnews.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/tempus-ai-expands-collaboration-gilead-sciences-maximize-insights-oncology-pipeline","source_event_id":"evt_c2c333980c01","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"36d352d8a54d3141","kind":"unusual_volume","published_at":"2026-04-09T13:16:46+00:00","publisher_domain":"rttnews.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["April 09, 2026"],"entities":[{"asset_class":"equity","name":"Tempus AI, Inc.","relevance":"high","symbol":"TEM","type":"company"},{"asset_class":"equity","name":"Gilead Sciences, Inc.","relevance":"high","symbol":"GILD","type":"company"}],"event_type":"other","information_gaps":["Unusual volume delta details are not provided: baseline volume, current volume, volume ratio, and direction (up/down) are missing from the supplied text.","No explicit statement is provided about whether the volume move (if any) is confirmed by news versus unexplained.","No specific catalyst timing relative to the volume event is provided beyond the announcement date/time in the article."],"key_facts":["RTTNews reports Tempus AI (TEM) announced an expanded, multi-year collaboration with Gilead Sciences (GILD).","Under the expanded agreement, Tempus will provide enterprise-wide access to its AI-driven Lens platform.","The collaboration is described as unlocking access to broader datasets across multiple indications.","The agreement includes integrating dedicated Tempus analytical services.","The combination of Gilead\u2019s scientific expertise and Tempus\u2019 real-world data insights is expected to maximize generation of key insights in oncology.","The article includes a CEO quote from Ryan Fukushima about multimodal depth and increasing the probability of success for life-altering medicines."],"numeric_claims":[],"primary_claim":"Tempus AI expanded its multi-year collaboration with Gilead Sciences to provide enterprise-wide access to its Lens platform and dedicated analytical services to build and advance an oncology pipeline.","relevance_score":0.45,"sentiment":"positive","source_quality":"high","summary":"Tempus AI (TEM) announced an expanded, multi-year collaboration with Gilead Sciences (GILD) to advance its oncology pipeline using Tempus\u2019 AI-driven Lens platform and analytical services.","topics":["oncology pipeline","AI-driven Lens platform","real world data","collaboration expansion","multi-year agreement"]},"source":"Nasdaq Markets","source_domain":"rttnews.com","summary":"(RTTNews) - Healthcare technology company Tempus AI, Inc. (TEM) Thursday announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (GILD) to build and advance its oncology pipeline.","tickers":["TEM","GILD"],"title":"Tempus AI Expands Collaboration With Gilead Sciences To Maximize Insights In Oncology Pipeline","url":"https://www.rttnews.com/3637925/tempus-ai-expands-collaboration-with-gilead-sciences-to-maximize-insights-in-oncology-pipeline.aspx"}... |